Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 3/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | GRM7 | Q14831 | 4/20 | 0.42 |
| ▸ | MTNR1A | P48039 | 3/20 | 0.41 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31141646 | 1.00 | IDO1 (0.56) | IDO1GAALMNAMAPTCA1 | |
| SCHEMBL3428492 | 0.80 | IDO1 (0.59) | IDO1LMNAMAPTCA1CA2 | |
| SCHEMBL173391 | 0.78 | IDO1 (0.61) | IDO1LMNAMAPTCA1CA2 | |
| SCHEMBL173810 | 0.77 | IDO1 (0.56) | IDO1GAALMNAMAPTGRM7 | |
| SCHEMBL13052260 | 0.73 | IDO1 (0.51) | IDO1LMNAMAPTGRM7MTNR1A | |
| SCHEMBL14433950 | 0.73 | SMN1; SMN2 (0.65) | IDO1GAALMNAMAPTNPC1 | |
| SCHEMBL12656187 | 0.72 | IDO1 (0.50) | IDO1LMNAMAPTCA1CA2 | |
| SCHEMBL15883185 | 0.72 | IDO1 (0.50) | IDO1LMNAMAPTCA1CA2 | |
| SCHEMBL30496747 | 0.72 | IDO1 (0.50) | IDO1LMNAMAPTCA1CA2 | |
| SCHEMBL1584190 | 0.72 | MAPT (0.54) | IDO1LMNAMAPTCA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4692083-A1 | NOVEL AZABICYCLE DERIVATIVES AND PHARMACEUTICAL COMPOSITION FOR INHIBITING AUTOTAXIN, COMPRISING SAME | Nextgen Bioscience Co., Ltd. (KR) | 2026-02-11 | — | — | EP | disclosed |
| US-12145929-B2 | Piperidine derivative and pharmaceutical composition for inhibiting autotaxin comprising same | NEXTGEN BIOSCIENCE CO., LTD. (KR) | 2024-11-19 | — | — | US | disclosed |
| US-20240279216-A1 | NOVEL PIPERIDINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION FOR INHIBITING AUTOTAXIN COMPRISING SAME | NEXTGEN BIOSCIENCE CO., LTD. (KR) | 2024-08-22 | — | — | US | disclosed |
| EP-4353720-A1 | NOVEL PIPERIDINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION FOR INHIBITING AUTOTAXIN COMPRISING SAME | Nextgen Bioscience Co., Ltd. (KR) | 2024-04-17 | — | — | EP | disclosed |
| WO-2023055178-A1 | NOVEL PIPERIDINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION FOR INHIBITING AUTOTAXIN COMPRISING SAME | 주식회사 넥스트젠바이오사이언스 | 2023-04-06 | — | — | WO | disclosed |
| US-20050065118-A1 | Organosulfur inhibitors of tyrosine phosphatases | METABASIS THERAPEUTICS, INC. | 2005-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240279216-A1 | NOVEL PIPERIDINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION FOR INHIBITING AUTOTAXIN COMPRISING SAME | ENPP2, UACA, ITCH | IDO1 588/4885GAA 2970/4885LMNA 4393/4885 |
| US-20050065118-A1 | Organosulfur inhibitors of tyrosine phosphatases | PTPRS, PTPRJ, PTPRCAP | IDO1 1533/4885GAA 2365/4885LMNA 4884/4885 |
| US-12145929-B2 | Piperidine derivative and pharmaceutical composition for inhibiting autotaxin comprising same | ENPP2, UACA, ACAT2 | IDO1 534/4885GAA 2728/4885LMNA 4317/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.